Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

BioSyent Releases Q2 and H1 2018 Results

Posted on: 22 Aug 18

TORONTO, Aug. 22, 2018 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today a summary of its financial results for the three and six months ended June 30, 2018. Key highlights include:

  • Record second quarter (Q2) 2018 Net Revenues of $5,909,423 increased by 5% versus a strong Q2 2017 in which growth over Q2 2016 was 29%
  • First half (H1) 2018 Net Revenues of $10,356,570 increased by 10% versus H1 2017
  • Q2 2018 Canadian Pharmaceutical Net Revenues of $5,031,138 increased by 16% versus Q2 2017 and International Pharmaceutical Net Revenues of $511,483 decreased by 31% versus Q2 2017 – An International Pharmaceutical order originally scheduled for Q2 2018 shipment was held back for shipping subsequent to quarter-end
  • H1 2018 Canadian Pharmaceutical Net Revenues of $8,796,776 increased by 14% versus H1 2017 and International Pharmaceutical Net Revenues of $1,077,324 increased by 4% versus H1 2017
  • Q2 2018 EBITDA1 of $2,088,638 increased by 3% versus Q2 2017
  • H1 2018 EBITDA1 of $3,566,405 increased by 11% versus H1 2017
  • Q2 2018 Net Income After Tax (NIAT) of $1,620,233 increased by 4% versus Q2 2017
  • H1 2018 NIAT of $2,763,363 increased by 13% versus H1 2017
  • Q2 2018 NIAT percentage to Net Revenues of 27% compares to 28% in Q2 2017
  • H1 2018 NIAT percentage to Net Revenues of 27% compares to 26% in H1 2017
  • Q2 2018 Fully Diluted EPS of $0.11 compares to $0.11 Fully Diluted EPS for Q2 2017
  • H1 2018 Fully Diluted EPS of $0.19 was $0.02 higher than H1 2017 Fully Diluted EPS of $0.17
  • Fully Diluted EPS for the Trailing Twelve Months ended June 30, 2018 was $0.38 as compared to $0.33 for the Trailing Twelve Months ended June 30, 2017
  • As at June 30, 2018, the Company had cash, cash equivalents, and short term investments totalling $21,014,159 as compared to $19,338,435 as at December 31, 2017 – a 9% increase
  • Total Shareholders’ Equity increased by 13% from $22,212,927 at December 31, 2017 to $25,183,197 at June 30, 2018
  • Return on Equity for the Trailing Twelve Months ended June 30, 2018 was 25%

“Q2 2018 was a record quarter for our Canadian pharmaceutical business and our business overall, marking BioSyent’s 32nd consecutive profitable quarter,” remarked René Goehrum, President and CEO of BioSyent. “Overall, our Canadian pharmaceutical business grew by 16% in Q2 2018 as both established brands and launch brands delivered growth during the quarter.  While our FeraMAX® products continued to drive growth in the business, we were also particularly pleased with the growth in our Hospital Business during the quarter, which delivered revenue growth of 71% over Q2 2017.”

The CEO’s presentation on the Q2 2018 Results is available at the following link:

The Company’s Interim Unaudited Condensed Consolidated Financial Statements and Management's Discussion and Analysis for the three and six months ended June 30, 2018 and 2017 will be posted on on August 22, 2018.

The Interim Unaudited Condensed Consolidated Financial Statements are available at

The Management's Discussion and Analysis is available at

For a direct market quote for the TSX Venture Exchange and other Company financial information, please visit

About BioSyent Inc.

Listed on the TSX Venture Exchange under the trading symbol “RX”, BioSyent is a profitable growth-oriented specialty pharmaceutical company focused on in-licensing or acquiring innovative pharmaceutical and other healthcare products that have been successfully developed, are safe and effective, and have a proven track record of improving the lives of patients.  BioSyent supports the healthcare professionals that treat these patients by marketing its products through its community, hospital and international business units.

As of the date of this press release, the Company has 14,519,603 common shares issued and outstanding.

In Canadian DollarsQ2 2018 Q2 2017 % Change H1 2018 H1 2017 % Change 
Net Revenues5,909,423 5,636,405 5%10,356,570 9,457,667 10%
Cost Of Goods Sold1,356,906 1,398,018 -3%2,387,800 2,187,048 9%
Gross Profit4,552,517 4,238,387 7%7,968,770 7,270,619 10%
Operating Expenses and Finance Income2,433,977 2,235,160 9%4,356,531 4,084,965 7%
Net Income Before Tax2,118,540 2,003,227 6%3,612,239 3,185,654 13%
Tax (including Deferred Tax)498,307   450,309 11%848,876   731,180 16%
Net Income After Tax1,620,233 1,552,918 4%2,763,363 2,454,474 13%
Net Income After Tax % to Net Revenues27%28% 27%26% 
EBITDA2,088,638 2,023,234 3%3,566,405 3,214,558 11%
EBITDA % to Net Revenues35%36% 34%34% 
  1. EBITDA –  is a Non-IFRS Financial Measure. The term EBITDA does not have any standardized meaning under International Financial Reporting Standards (IFRS) and therefore may not be comparable to similar measures presented by other companies. The Company defines EBITDA as earnings before interest income or expense, income taxes, depreciation and amortization.
BioSyent Inc.
 Interim Unaudited Condensed Consolidated Statements of Financial Position
AS AT June 30, 2018December 31, 2017% Change
Trade and other receivables$2,507,474$2,236,69512%
Inventory 1,734,295 908,82591%
Prepaid expenses and deposits 215,454 147,32646%
Income tax recoverable 54,543 71,924-24%
Derivative asset 146,179 - 
Cash, cash equivalents and short-term investments 21,014,159 19,338,4359%
Current Assets 25,672,104 22,703,20513%
Equipment 273,197 290,926-6%
Intangible assets 1,928,250 1,670,21015%
Loans receivable 395,813 393,860 
Deferred tax asset 44,246 46,647-5%
TOTAL NON CURRENT ASSETS 2,641,506 2,401,64310%
TOTAL ASSETS$28,313,610$25,104,84813%
Current liabilities$2,771,447$2,615,5946%
Deferred tax liability 358,966 276,32730%
Long term debt - -0%
Total Equity 25,183,197 22,212,92713%

For further information please contact:

Mr. René C. Goehrum
President and CEO
BioSyent Inc.
Tel: (905) 206-0013

This press release may contain information or statements that are forward-looking. The contents herein represent our judgment, as at the release date, and are subject to risks and uncertainties that may cause actual results or outcomes to be materially different from the forward-looking information or statements. Potential risks may include, but are not limited to, those associated with clinical trials, product development, future revenue, operations, profitability and obtaining regulatory approvals.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.


Last updated on: 22/08/2018

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.